Pharmacists in Kimball, MI Accepting Medicare

8 Pharmacists found. Showing 1 - 8

Mr. Edward Adam Rozanski, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5277 Lapeer Rd, Kimball, MI 48074 Phone: 810-984-8200    Fax: 810-984-1633

Lena Matti, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4514 Gratiot Rd, Kimball, MI 48074 Phone: 810-364-6980

Martha Ann Fisher, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4514 Gratiot Rd, Kimball, MI 48074 Phone: 810-364-6980    Fax: 810-364-1883

Ms. Brenda Recker, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5277 Lapeer Rd, Kimball, MI 48074 Phone: 810-984-8200    Fax: 810-984-1633

Sanaa Elghalmi Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4514 Gratiot Rd, Kimball, MI 48074 Phone: 810-364-6980

Mrs. Karen J Hennesey, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5283 Lapeer Rd, Kimball, MI 48074 Phone: 810-325-1761

Stephanie Ann Gemmete Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4514 Gratiot Rd, Kimball, MI 48074 Phone: 810-364-6980

Mr. Dennis Albert Vollmer, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5277 Lapeer Rd, Kimball, MI 48074 Phone: 810-984-8200    Fax: 810-984-1633

News Archive

Align Networks announces significant investment from General Atlantic

Align Networks, Inc., a leading provider of workers' compensation physical medicine programs, today announced a significant investment from global growth equity firm General Atlantic LLC.

UCSD now offer novel weight-loss surgery, gastric plication

Patients seeking a weight-loss surgery that does not require an implanted device or permanent change to their anatomy, have a new clinical trial option at UC San Diego Health System. Santiago Horgan, MD, chief of minimally invasive surgery, and his team, now offer gastric plication, a novel surgery that folds the stomach into a smaller, more compact size.

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Diabetes drug metformin exhibits potential against tobacco-induced lung tumors

Metformin, a drug commonly used to treat type 2 diabetes, shows potential in the prevention of tobacco-induced lung tumors, according to early research conducted at the National Cancer Institute (NCI).

Three-year results of SPIRIT III clinical trial reaffirms safety of PROMUS and TAXUS Express stents

Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio of drug-eluting stents, including the first-generation TAXUS((R)) Express(2)(TM) Paclitaxel-Eluting Coronary Stent System and the XIENCE V(TM) (PROMUS((R))) Everolimus-Eluting Coronary Stent System.

Read more Medical News

› Verified 4 days ago